Dr. James H. Doroshow has been the Deputy Director for Clinical and Translational Research of the National Cancer Institute since 2011, and the Director of NCI’s Division of Cancer Treatment and Diagnosis since 2004.
He also continues to pursue his own research program as a Senior Investigator in the Developmental Therapeutics Branch of the NCI’s intramural Center for Cancer Research. He is the author of over 500 full-length publications in the areas of molecular pharmacology, the role of oxidant stress in tumour cell signal transduction, and novel therapeutic approaches to solid tumours; at the time of his move to his current position, Dr. Doroshow had received over 25 years of peer-reviewed research funding from the NCI.
From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope Comprehensive Cancer Center’s Department of Medical Oncology and Therapeutics Research, and Associate Cancer Center Director for Clinical Investigation. He has served on the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration, the Medical Oncology Board of the American Board of Internal Medicine, and as Chair of two NIH study sections: Experimental Therapeutics II and Subcommittee A, Cancer Centers.
He is currently a member of both the Forum on Drug Discovery, Development, and Translation and the National Cancer Policy Forum of the National Academy of Medicine of the National Academies of Science. He was the Associate Editor for Oncology of the 25th Edition of the Cecil Textbook of Medicine, and Co-Editor of the 5th and 6th Editions of Abeloff’s Clinical Oncology.
Dr. Doroshow received his A.B. degree magna cum laude from Harvard College in 1969 and graduated from Harvard Medical School alpha omega alpha in 1973. Following an Internal Medicine residency at the Massachusetts General Hospital, he completed a fellowship in Medical Oncology at the Medicine and Clinical Pharmacology Branches of the National Cancer Institute, NIH.